We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$64.8B
1-Year Est. Return
42.7%
This Fund
S&P 500
This Quarter
Est. Return
+27.07%
1 Year Est. Return
+42.7%
3 Year Est. Return
+139.29%
5 Year Est. Return
+204.38%
10 Year Est. Return
+829.83%
AUM
$39.1B
AUM Growth
+$5.57B
(+17%)
Cap. Flow
-$1.33B
Cap. Flow
% of AUM
-3.4%
Top 10 Holdings %
Top 10 Hldgs %
25.2%
Holding
834
New
111
Increased
262
Reduced
309
Closed
110
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Royalty Pharma
RPRX
|
+$2.28B |
| 2 |
Otis Worldwide
OTIS
|
+$193M |
| 3 |
Burlington
BURL
|
+$191M |
| 4 |
AbbVie
ABBV
|
+$178M |
| 5 |
Wayfair
W
|
+$144M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$1.66B |
| 2 |
Lockheed Martin
LMT
|
+$339M |
| 3 |
Johnson & Johnson
JNJ
|
+$262M |
| 4 |
Pfizer
PFE
|
+$167M |
| 5 |
Target
TGT
|
+$141M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.52% |
| 2 | Healthcare | 19.78% |
| 3 | Consumer Discretionary | 13.09% |
| 4 | Financials | 11.33% |
| 5 | Industrials | 8.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Oracle
ORCL
$409B
| $112M | 0.29% |
2,031,016
-435,548
| -18% | -$23.1M |
|
77
BioMarin Pharmaceuticals
BMRN
$11.6B
| $110M | 0.28% |
894,000
+559,124
| +167% | +$55.6M |
|
78
Wells Fargo
WFC
$266B
| $110M | 0.28% |
4,294,432
-88,842
| -2% | -$2.43M |
|
|
ALXN
79
DELISTED
Alexion Pharmaceuticals
ALXN
| $109M | 0.28% |
968,058
-86,452
| -8% | -$9.18M |
|
80
Boeing
BA
$185B
| $106M | 0.27% |
579,132
+196,462
| +51% | +$30.2M |
|
81
Chubb
CB
$134B
| $105M | 0.27% |
827,624
+508,800
| +160% | +$59M |
|
82
TE Connectivity
TEL
$59.4B
| $103M | 0.26% |
1,265,557
-539,631
| -30% | -$40.6M |
|
83
S&P Global
SPGI
$123B
| $102M | 0.26% |
309,561
+29,309
| +10% | +$8.81M |
|
84
Norfolk Southern
NSC
$75.6B
| $101M | 0.26% |
578,055
+210,549
| +57% | +$35.7M |
|
85
Gentex
GNTX
$4.99B
| $101M | 0.26% |
3,912,954
-334,739
| -8% | -$8.39M |
|
86
Starbucks
SBUX
$118B
| $99.4M | 0.25% |
1,350,609
+21,756
| +2% | +$1.63M |
|
87
Chevron
CVX
$385B
| $98.5M | 0.25% |
1,103,393
-1,087,300
| -50% | -$97.3M |
|
88
CVS Health
CVS
$134B
| $98M | 0.25% |
1,508,774
+16,700
| +1% | +$1.05M |
|
89
Under Armour
UAA
$2.89B
| $97.3M | 0.25% |
9,987,986
-4,046,514
| -29% | -$38.4M |
|
90
Blackrock
BLK
$175B
| $97M | 0.25% |
178,280
+32,800
| +23% | +$16.6M |
|
|
VISN
91
Vistance Networks Inc
VISN
$2.72B
| $96.5M | 0.25% |
11,582,865
+3,713,258
| +47% | +$36.7M |
|
92
IBM
IBM
$213B
| $95M | 0.24% |
822,773
-236,396
| -22% | -$27.5M |
|
|
BECN
93
DELISTED
Beacon Roofing Supply, Inc.
BECN
| $94.9M | 0.24% |
3,599,716
+352,553
| +11% | +$7.88M |
|
94
AutoZone
AZO
$48.8B
| $94.5M | 0.24% |
83,811
+73,096
| +682% | +$77M |
|
95
Intuitive Surgical
ISRG
$135B
| $94.2M | 0.24% |
495,684
-51,684
| -9% | -$9.26M |
|
96
Regeneron Pharmaceuticals
REGN
$78.2B
| $94.1M | 0.24% |
150,886
+84,808
| +128% | +$48.1M |
|
|
ATVI
97
DELISTED
Activision Blizzard
ATVI
| $92.4M | 0.24% |
1,217,166
+350,222
| +40% | +$24.4M |
|
98
Carrier Global
CARR
$52.1B
| $91.9M | 0.24% |
+4,134,282
| New | +$76.8M |
|
99
Amphenol
APH
$201B
| $91.8M | 0.24% |
3,832,336
+2,958,244
| +338% | +$66M |
|
|
NVMI
100
Nova
NVMI
$12.5B
| $91.2M | 0.23% |
1,893,286
-332,736
| -15% | -$14.1M |
|
Similar funds
Adage Capital Partners's Q2 2020 Portfolio in Review
As of Q2 2020, Adage Capital Partners held 834 positions worth $39.1B, up 17% from $33.5B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Adage Capital Partners withdrew a net $1.33B in Q2 2020, closing 110 positions and reducing 309 holdings. Its most notable exit was Allergan plc, an estimated $1.66B position sold in full.
By sector, the portfolio is most concentrated in Technology at 22% of assets, up from 19% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Adage Capital Partners opened a new position in Royalty Pharma worth $2.23B.
- Adage Capital Partners's largest Q2 2020 buy was Royalty Pharma: 46,015,330 shares worth $2.23B.
- Adage Capital Partners added most to Burlington in Q2 2020, an estimated $191M increase.
- Adage Capital Partners's biggest Q2 2020 reduction was Lockheed Martin, cutting an estimated $339M.
- Adage Capital Partners fully exited Allergan plc in Q2 2020, selling an estimated $1.66B.
- Adage Capital Partners's ten largest holdings make up 25% of its $39.1B portfolio in Q2 2020.
- Adage Capital Partners opened 111 new positions and closed 110 in Q2 2020.
- Adage Capital Partners's portfolio value rose 17% quarter-over-quarter to $39.1B.
Based on Adage Capital Partners's 13F filing for Q2 2020, filed 14 Aug 2020.